menu
    • menu
    [{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ledaborbactam Etzadroxil","moa":"beta-lactamases","graph1":"Undisclosed","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VNRX-7145","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VNRX-7145","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VNRX-7145","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VNRX-7145","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Ceftibuten","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ BARDA"}]

    Find Clinical Drug Pipeline Developments & Deals for Ledaborbactam Etzadroxil

    Menu

    Ledaborbactam Etzadroxil

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Basilea Pharmaceutica

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftibuten,Ledaborbactam Etzadroxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : BARDA

                            Deal Size : $159.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Basilea Awarded BARDA Contract for the Development of Ceftibuten-Ledaborbactam

                            Details : The funding will support the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a BL/BLI combination, for the treatment of cUTIs, including pyelonephritis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : Ceftibuten,Ledaborbactam Etzadroxil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : BARDA

                            Deal Size : $159.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Particip...

                            Details : Ledaborbactam Etzadroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2024

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants

                            Details : VNRX-7145 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

                            Details : VNRX-7145 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers

                            Details : VNRX-7145 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2021

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            VenatoRx Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

                            Details : VNRX-7145 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 28, 2020

                            Lead Product(s) : Ledaborbactam Etzadroxil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth